Hemoglobin Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Hemoglobin blood test

Hemoglobin (Hb). Also called: Hb, Hgb, Haemoglobin

Biomarker guideLast updated: October 30, 2026

Hemoglobin blood test: what it measures, Labcorp's adult female range, the WHO 2024 anaemia cutoffs, what raises and lowers it, and 21 peptides with measured effects, from EPO to the GnRH drugs.

LOINC 718-7Blood

Part of the complete blood count (CBC). The panel page lists every value on the report.

At a glance

What it measuresThe concentration of hemoglobin, the iron-containing oxygen carrier inside red cells, in whole blood
Unitsg/dL in the US; g/L in WHO documents and many other countries (13.0 g/dL = 130 g/L)
Labcorp adult range11.1-15.9 g/dL for women. Labcorp's published sample reports include no adult male range
WHO anaemia cutoffs (2024)Below 13.0 g/dL for men and below 12.0 g/dL for non-pregnant women aged 15-65
SampleWhole blood in an EDTA (lavender-top) tube; no fasting listed
Ordered asPart of every complete blood count (CBC), or alone (Labcorp 005041, Quest 510)
Peptides with data21, led by Erythropoietin (EPO); the GnRH drugs lower it in men and raise it in women with fibroid bleeding

What is Hemoglobin?

Hemoglobin is the iron-containing protein that fills red blood cells. The blood test reports its concentration in whole blood, usually in grams per deciliter (g/dL). WHO defines anaemia as circulating red blood cells that are insufficient to meet physiological oxygen-carrying needs, and uses hemoglobin concentration to diagnose it.

Hemoglobin is reported on every complete blood count beside hematocrit (the volume of packed red cells relative to whole blood, reported as a percentage) and the red cell count. The three usually move together, so this page also includes peptide data measured as hematocrit or red cell count, labelled in the Measured column.

Sources: [1] [2] [3]

How it is made and regulated

Where it is made

Red cells, and the hemoglobin inside them, are made from progenitor cells in the bone marrow. The hormone erythropoietin, produced in the kidney or liver of adults, stimulates these progenitors to proliferate and mature into red blood cells. Cloning the human erythropoietin gene in 1985 made it possible to produce biologically active hormone in cultured cells, the basis of Erythropoietin (EPO).

Iron supply limits how much hemoglobin can be made. In inflammation, cytokines (interleukin-6 most prominently) drive up the iron-regulatory hormone hepcidin, which traps iron inside macrophages and gut cells; the iron supply to hemoglobin synthesis becomes limiting, and anaemia follows.

Sources: [4] [5] [6]

What controls it

Erythropoietin regulates the level of oxygen in the blood by modulating the number of circulating red cells. Androgens also stimulate red-cell production. When men with prostate cancer start androgen deprivation therapy, hematocrit falls; in a 6-month study, hemoglobin was 0.6 g/dL lower than in men not on treatment.

Testosterone therapy pushes the other way. The Endocrine Society lists elevated hematocrit as a reason not to start testosterone and asks clinicians to measure hematocrit during the first year. Testosterone labels say to check that hematocrit is not elevated before starting, to re-check it during treatment, and to stop if it becomes elevated.

Sources: [4] [7] [8] [9] [10] [11] [12]

How it travels in the blood

The test measures hemoglobin in a volume of whole blood, so plasma volume matters as well as red-cell mass. In pregnancy, plasma volume rises 42% above non-pregnant levels by weeks 28-34 and 48% by weeks 35-38. That dilution is one reason WHO sets lower anaemia cutoffs in pregnancy.

Endurance training can have a similar effect: "sports anaemia" is probably due to an expanded plasma volume, since true red-cell deficiency is rare in athletes.

Sources: [13] [1] [14]

How long it lasts

A red blood cell lives about 120 days. Macrophages in the spleen and liver, and, recent studies show, in the bone marrow, then remove it. The iron in hemoglobin is recycled for new cells and the heme is broken down to bilirubin.

HbA1c reflects average glucose over this red-cell lifespan. Conditions that shorten it, such as hemolytic anaemia, give a falsely low HbA1c.

Sources: [2] [15]

What it does

Hemoglobin lets red cells carry oxygen; anaemia is the state in which circulating red cells cannot meet the body's oxygen-carrying needs.

Red-cell concentration also changes how fast blood settles in a tube. The size of the settling red-cell aggregates is inversely proportional to the hematocrit, which explains the raised erythrocyte sedimentation rate (ESR) seen in anaemia.

Sources: [1] [16]

Reference ranges

Labs set their own ranges. Labcorp publishes CBC ranges only on its sample reports, and every adult on those reports is a woman, so the first table shows Labcorp's adult female range and says plainly that no adult male range is published. Quest's test directory lists the range as "See Laboratory Report".

The second table is not a lab range. It is WHO's 2024 set of hemoglobin cutoffs for diagnosing anaemia, each based on the 5th percentile of healthy populations; WHO publishes them in g/L, shown here converted to g/dL.

Labcorp (test 005009)

Method: Automated cell counter with mixed technologies. Labcorp test page (retrieved October 30, 2026).

GroupRange (g/dL)
Women, adult (sample reports for women aged 26, 46 and 60)11.1-15.9
Men, adultNot published in Labcorp's sample reports
Children and teens
GroupRange (g/dL)
Boys, 15 years (sample report; a teen range, not an adult range)12.6-17.7

Ranges as printed on Labcorp's published sample reports for tests 005009 (2026 and 2024), 005041 (2016) and 028142 (2020). The 15-year-old's range is shown only in the teen block; it is not an adult male range.

WHO 2024 anaemia cutoffs (threshold-based, not normal-range reference)

Clinical guideline thresholds (not a commercial lab's normal range). Method: Hemoglobin below the 5th percentile of healthy populations defines anaemia (Table 2). Guideline document (retrieved October 30, 2026).

GroupRange (g/dL)
Men, 15-65 years: anaemia below<13.0 (130 g/L)
Non-pregnant women, 15-65 years: anaemia below<12.0 (120 g/L)
Pregnancy, first trimester<11.0 (110 g/L)
Pregnancy, second trimester<10.5 (105 g/L)
Pregnancy, third trimester<11.0 (110 g/L)
Children and teens
GroupRange (g/dL)
Children, 6-23 months<10.5 (105 g/L)
Children, 24-59 months<11.0 (110 g/L)
Children, 5-11 years<11.5 (115 g/L)
Children, 12-14 years (boys and non-pregnant girls)<12.0 (120 g/L)

Smokers (WHO Table 5): add 3 g/L (0.3 g/dL) to the cutoff when the amount is unknown or under 10 cigarettes a day, 5 g/L for 10-19 a day and 6 g/L for more than 20 a day, or subtract the same amount from the measured result.

Use the range printed on your own report. A lab range describes typical healthy results; a WHO cutoff answers a different question (is this anaemia?). Neither one alone is a diagnosis.

Sources: [17] [18] [19] [20] [1]

What raises it

FactorHowHow much
SmokingLifestyleSmokers had significantly higher red cell counts, hemoglobin and hematocrit than non-smokers; the authors suggest smoking impairs gas exchange in the lung, leading to secondary polycythemia.WHO adds 3 g/L (fewer than 10 a day or amount unknown), 5 g/L (10-19 a day) or 6 g/L (more than 20 a day) to the anaemia cutoff for smokers [21] [1]
Testosterone therapyMedicationAndrogens increase red-cell mass. Labels require a hematocrit check before starting and during treatment, and say to stop if hematocrit becomes elevated.No published magnitude [9] [10] [11] [12] [8]
Erythropoiesis-stimulating agentsPeptideErythropoietin (EPO) and related drugs stimulate red-cell production directly.Labels: reduce the dose if hemoglobin rises more than 1 g/dL in any 2-week period [22]
High altitudePhysiologyIn 3,485 healthy adults living at four altitudes, red cell count, hemoglobin and hematocrit all rose significantly with altitude, from 1,400 m to 4,100 m.No published magnitude [23]
Sitting or standing before the drawPhysiologyHemoglobin, red cell count and hematocrit rise significantly when you move from lying down to a more upright position, probably because of increased hydrostatic pressure.No published magnitude [24] [25]

What lowers it

FactorHowHow much
Iron deficiency and inflammationConditionToo little iron, or iron locked away by hepcidin during inflammation, limits hemoglobin synthesis.No published magnitude [6]
PregnancyPhysiologyPlasma volume expands faster than red-cell mass and dilutes hemoglobin; WHO uses lower cutoffs by trimester.Plasma volume +42% (weeks 28-34) and +48% (weeks 35-38) above non-pregnant levels [13] [1]
Androgen deprivation therapyMedicationRemoving testosterone removes an androgen drive on red-cell production.Hemoglobin -0.6 g/dL (95% CI -0.8 to -0.3) and hematocrit -1.9% vs men not on ADT, at 6 months [7]
Copper deficiencyNutritionCopper deficiency is an under-recognized cause of reversible anaemia, often with low neutrophils, and can be mistaken for myelodysplastic syndrome.No published magnitude [26]
Endurance exerciseLifestyleTraining expands plasma volume ("sports anaemia"), and red cell count and hemoglobin modestly decreased after a half-marathon.No published magnitude [14] [27]
A large mealLifestyleAn 800-calorie meal lowered hematocrit, and the effect lasted 6 hours.No published magnitude [25]

Peptides that affect Hemoglobin

Peptides with measured effects on hemoglobin, hematocrit or red-cell count, from human trials, FDA labels and named animal studies. GnRH drugs appear twice when the effect runs in opposite directions in different groups: hemoglobin falls in men on androgen deprivation and rises in women whose fibroid bleeding stops. "No clear effect" rows were measured; they are not inferred.

PeptideMeasuredEffect on HemoglobinSize of effectEvidence
BuserelinWomen with fibroidsHemoglobinRaises22 women given intranasal buserelin 1200 micrograms/day for 6 months: hemoglobin values normalized in all anemic patientsShrinking fibroids and less bleeding let low hemoglobin return to normal. [28]Human trials
GoserelinWomen with fibroids and severe anemiaHemoglobinRaises16 women given goserelin 3.6 mg every 28 days: mean hemoglobin rose from 7.4 g/dL to 13.2 g/dL at 3 months and hematocrit from 26.1% to 39.8%Goserelin stopped heavy bleeding (13 of 16 women became amenorrheic), and hemoglobin recovered. [29]Human trials
IGF-1 (Insulin-Like Growth Factor 1)HemoglobinRaisesChildren with Laron syndrome on IGF-I therapy: hemoglobin 11.55 to 13.01 g/dL (p<0.001), hematocrit 34.94% to 38.52%, red cells 4.66 to 4.93 x10^6Replacing IGF-I in IGF-I deficiency stimulated red-cell production. [30]Human trials
NafarelinHemoglobinRaisesWomen with fibroids or heavy bleeding before hysterectomy (placebo-controlled, 166 analysed, 3 months): nafarelin led to a rise in hemoglobin of 5.5 g/L (0.55 g/dL). A literature review found the same pattern across trialsLess uterine bleeding on nafarelin raised mean hemoglobin, in women with and without anemia. [31] [32]Human trials
TriptorelinWomen with fibroidsHemoglobinRaisesRandomized trial, 125 women given triptorelin or leuprorelin 3.75 mg every 28 days for 3 months: hemoglobin and serum iron rose significantly in both groups (P<0.05). The abstract gives no mean changeWith bleeding suppressed (97% amenorrhea on triptorelin), hemoglobin and iron recovered. [33]Human trials
BuserelinMen on androgen suppression for prostate cancerHemoglobinLowers69 men on 2-year buserelin after salvage radiotherapy: maximal hemoglobin drop 16.0 g/L (1.6 g/dL), at 16 months (p<0.0001). Recovery after stopping was slowHemoglobin and hematocrit fell and recovered in step with testosterone. [34]Human trials
GoserelinMen on combined androgen blockade (goserelin plus flutamide)HemoglobinLowers141 men on goserelin plus flutamide: hemoglobin fell at least 1 g/dL (mean 2.1 g/dL) in 75% after 2 months, and at least 2 g/dL (mean 3.1 g/dL) in 81% after 2 more months with radiotherapy. No blood loss or hemolysis was found. The label lists anemia among adverse eventsThe fall tracked the drop in testosterone; this study combined goserelin with the antiandrogen flutamide. [35] [36]Human trials
LeuprolideMen on androgen deprivation for prostate cancerHemoglobinLowersMen with metastatic prostate cancer (chart review, 135 men): mean hemoglobin fell 1.66 g/dL on leuprolide alone (p<0.0001). Label (prostate cancer): decreased hemoglobin/hematocrit/RBC recorded in at least 5% of patientsLowering testosterone removes an androgen drive on red-cell production, so hemoglobin drifts down, sometimes into the anemic range. [37] [38]Human trials
LiraglutideHemoglobinLowersLEADER trial (type 2 diabetes): hemoglobin fell 2.6 g/L (0.26 g/dL) on liraglutide at the first measurement (p<0.01)A small fall in a large cardiovascular-outcomes trial. [39]Human trials
AnamorelinHemoglobinNo clear effectMeasured as adverse events, phase 2 (lung cancer cachexia, 12 weeks): "hemoglobin decreased" in 21.5% (50 mg) and 20.0% (100 mg) vs 25.9% on placeboHemoglobin falls were no more common than on placebo. [40]Human trials
Enkephalin (Met-enkephalin / Leu-enkephalin)HemoglobinNo clear effectMeasured, no change: [Met5]-enkephalin (opioid growth factor) infusions; no statistical change in hematologic values from baseline throughout the studyHematology was monitored and did not move. [41]Human trials
Human Chorionic Gonadotropin (hCG)HematocritNo clear effectMeasured, no change: men with hypogonadal symptoms on weekly hCG had no change in hematocrit (retrospective)Unlike testosterone itself, hCG did not raise hematocrit in this cohort. [42]Human trials
Melanotan IHemoglobinNo clear effectMeasured, no change: 38 patients with erythropoietic protoporphyria on afamelanotide; mean hemoglobin before and during treatment remained stableRed-cell indices such as RDW did shift, but hemoglobin held steady. [43]Human trials
MK-677 (Ibutamoren)HemoglobinNo clear effectMeasured: 2-year trial in older adults with a complete blood count monitored; the authors report no changes in routine laboratory testsA weak null: CBC was monitored, but individual values were not published. [44]Human trials
TeriparatideRBCNo clear effectMeasured, no change: 23 postmenopausal women on 20 mcg daily for 24 months; no differences in complete blood count profiles, which included red blood cellsTeriparatide raised circulating stem cells but left the routine blood count unchanged. [45]Human trials
CarbetocinHemoglobinUnclearWomen after delivery, compared with oxytocin: one randomized trial found slightly lower post-delivery hemoglobin and more women with a drop of 2 g/dL or larger on heat-stable carbetocin; another trial found the smallest hemoglobin decrease (-0.99 g/dL) on carbetocinCarbetocin prevents postpartum bleeding; trials against oxytocin point in different directions for hemoglobin. [46] [47]Human trials
Erythropoietin (EPO)HemoglobinRaisesLabel boxed warning: in chronic kidney disease trials, targeting a hemoglobin level of greater than 11 g/dL raised the risk of death, serious cardiovascular reactions and stroke. If hemoglobin rises more than 1 g/dL in any 2-week period, reduce the dose by 25% or moreErythropoietin drives red-cell production, so hemoglobin rises; the labels cap both how high it is targeted and how fast it may climb. [22] [48] [49]FDA label
LeuprolideWomen with fibroids and anemia, given with ironHemoglobinRaisesLabel (Lupron Depot 3.75 mg with iron, 3 months): hematocrit rose at least 6% and hemoglobin at least 2 g/dL in 77% of women; mean change +4.2 g/dL hemoglobin and +10.1% hematocrit. Some women respond to iron aloneStopping heavy fibroid bleeding lets hemoglobin recover; the label approves it only alongside iron. [50]FDA label
GanirelixHematocritLowersNo size given: the label reports downward shifts in hematocrit in the ganirelix group in controlled trials, clinical significance not determinedA short IVF antagonist course; the label notes a hematocrit shift without a figure. [51]FDA label
HirudinHemoglobinLowersLabel (lepirudin, HAT-1/HAT-2): anemia or isolated drop in hemoglobin in 13.1% of all patients, and in 12.4% of patients with thromboembolic complications vs 1.1% of historical controls; listed with bleeding eventsAn anticoagulant: the hemoglobin drops come from bleeding, not from an effect on red-cell production. [52]FDA label
LanreotideHemoglobinLowersLabel: anemia in 7% of patients in pooled Studies 1 and 2, and in 3% across all pooled studiesAnemia is listed among adverse reactions to the somatostatin analog. [53]FDA label
TriptorelinMen with prostate cancerHemoglobinLowersLabel: decreased hemoglobin and RBC count (11.25 mg, at the Day 253 visit) and decreased hemoglobin (22.5 mg), each in 10% or more of patients; most changes were mild to moderateTriptorelin suppresses testosterone, and the label records hemoglobin falling during treatment. [54]FDA label
PasireotideHemoglobinUnclearLabel (phase III, Cushing's disease): anemia in 4%, listed among reactions under 5%Reported at a low rate, with no placebo group to compare against. [55]FDA label
CapromorelinHemoglobinLowersCats with chronic kidney disease (label field study): anemia in 9.3% on capromorelin vs 1.7% on vehicle. In the published trial, mean hemoglobin was significantly lower on capromorelin on days 15 and 55A veterinary ghrelin agonist; the data are from cats. [56] [57]Animal studies
LL-37RBCNo clear effectMeasured, no change: mice given intranasal LL-37 had red cell counts no different from saline controlsMouse data from a lung-injury model. [58]Animal studies

What high or low results can mean

A high result

A high hemoglobin, usually with a high hematocrit, means more red-cell mass in each volume of blood. An increase in red-cell mass may increase the risk of blood clots, which is why testosterone labels act on it.

  • Smoking (secondary polycythemia)
  • Testosterone therapy
  • Living at high altitude
  • Sitting or standing before the draw (a small posture effect)

Next step: Repeat the test after sitting quietly, and discuss a result that stays high with a clinician, especially on testosterone, where labels say to stop treatment until hematocrit falls.

Sources: [21] [9] [23] [24]

A low result

A low hemoglobin is anaemia when it falls below the WHO cutoff for your sex, age and pregnancy status. The type of anaemia is read from the red-cell indices: red cell size (MCV) and size variation (RDW) help separate iron deficiency from thalassemia trait and the anaemia of chronic disease.

  • Iron deficiency or heavy menstrual bleeding (for example from fibroids)
  • Inflammation, through hepcidin
  • Pregnancy (dilution)
  • Androgen deprivation therapy
  • Copper deficiency
  • Shortened red-cell survival (hemolysis)

Next step: Ask whether ferritin and the red-cell indices were checked, and discuss the cause with a clinician before taking iron.

Sources: [1] [59] [50] [6] [15]

How the test works

SampleWhole blood from a full EDTA (lavender-top) tube. Quest asks for 1 mL (0.5 mL in a microtainer) and rejects grossly hemolyzed, clotted or frozen samples.
FastingNeither Labcorp nor Quest lists fasting for hemoglobin. An older study found that an 800-calorie meal lowered hematocrit for 6 hours and advised a morning draw, fasting or after a light breakfast.
TimingPosture matters: hemoglobin and hematocrit rise when you move from lying down to sitting or standing. The 1965 study advised sitting for at least 30 minutes before the draw; at minimum, compare results taken the same way.
Lab differencesQuest measures hemoglobin by electronic cell sizing and counting (cytometry) on an automated analyzer, and samples keep for 48 hours at room temperature. Red-cell index values depend on the analyzer technology, so track trends at one lab.
RetestingWithin-person variation is small: a 2019 meta-analysis put it below 3% for red-cell values (reticulocytes aside), and a 2018 study advised calculating the change needed to be meaningful by monitoring time and sex for hemoglobin.
Labcorp order code005041: Hemoglobin (Hb)
Quest Diagnostics order code510: Hemoglobin
LOINC codes
  • 718-7: Hemoglobin [Mass/volume] in Blood
LOINC 718-7 on loinc.org

Sources: [20] [25] [24] [60] [61] [62] [63]

History

Three milestones still shape how a hemoglobin result is read: red-cell indices for classifying anaemia, recombinant erythropoietin, and WHO's 2024 update of the anaemia cutoffs.

  1. 1934M.M. Wintrobe publishes his classification of anaemias by red-cell volume and hemoglobin content, still the basis of reading MCV and MCH 80 years later. [60]
  2. 1985The human erythropoietin gene is cloned and expressed in cultured cells, producing biologically active hormone and opening the way to recombinant Erythropoietin (EPO). [4] [5]
  3. 2024WHO publishes updated hemoglobin cutoffs to define anaemia, based on the 5th percentile of healthy populations, with adjustments for smoking. [1]

FAQ

What is a normal hemoglobin level?

Labcorp prints 11.1-15.9 g/dL for adult women. WHO defines anaemia as below 13.0 g/dL for men and below 12.0 g/dL for non-pregnant women aged 15-65. Labs differ, so read your result against the range printed on your own report.

Sources: [17] [1]

Why is there no Labcorp range for adult men on this page?

Labcorp publishes CBC ranges only on its sample reports. Every adult on those reports is a woman (aged 26, 46 and 60); the only male example is a 15-year-old, and a teenager's range is not an adult range. Quest's directory says "See Laboratory Report". Until a verified adult male lab range is available, use the range on your own report; for anaemia, the WHO cutoff for men is below 13.0 g/dL.

Sources: [17] [18] [19] [20] [1]

Is the WHO cutoff the same as a normal range?

No. A lab range describes typical healthy results. The WHO cutoffs are thresholds for diagnosing anaemia, set at the 5th percentile of healthy populations, so about 1 in 20 healthy people falls below them.

Sources: [1]

Does smoking change hemoglobin?

Yes. Smokers have higher red cell counts, hemoglobin and hematocrit. WHO adds 3 to 6 g/L to the anaemia cutoff for smokers, depending on cigarettes per day, so the same result can count as anaemia in a heavy smoker but not in a non-smoker.

Sources: [21] [1]

How does testosterone therapy affect hemoglobin and hematocrit?

Androgens increase red-cell mass. The Endocrine Society lists elevated hematocrit as a reason not to start testosterone and recommends measuring hematocrit during the first year of treatment. Testosterone labels say to check hematocrit before starting, re-check it during treatment, and stop if it becomes elevated until it falls.

Sources: [8] [9] [10] [11] [12]

Why is hemoglobin lower in pregnancy?

Plasma volume expands by up to 48% above non-pregnant levels late in pregnancy, which dilutes hemoglobin. WHO uses lower cutoffs: below 11.0 g/dL in the first and third trimesters and 10.5 g/dL in the second.

Sources: [13] [1]

Can exercise lower hemoglobin?

It can lower the concentration. Endurance training expands plasma volume ("sports anaemia"), and hemoglobin modestly decreased after a half-marathon in trained runners. True red-cell deficiency is rare in athletes.

Sources: [14] [27]

What is the difference between hemoglobin and hematocrit?

Hemoglobin is the concentration of the oxygen-carrying protein. Hematocrit is the volume of packed red cells relative to whole blood, reported as a percentage. Both are on every CBC and usually move together.

Sources: [3] [1]

Do I need to fast for a hemoglobin test?

Labcorp and Quest list no fasting requirement. An 800-calorie meal lowered hematocrit for about 6 hours in an older study, so a morning draw before a large meal gives the most comparable results.

Sources: [20] [25]

How much can hemoglobin vary between two tests?

Less than most blood tests: within-person variation for red-cell values is under 3%. Posture before the draw (lying versus sitting) can shift it, so compare results taken the same way.

Sources: [61] [24]

Which peptides affect hemoglobin?

Erythropoietin (EPO) raises it, and its labels cap how high and how fast. The GnRH drugs (Leuprolide, Goserelin, Triptorelin, Buserelin) lower it in men on androgen deprivation and raise it in women whose fibroid bleeding stops. IGF-I therapy raised it in children with Laron syndrome. The full table is above.

Sources: [22] [37] [50] [30]

Can anaemia change other blood tests?

Yes. A shortened red-cell lifespan gives a falsely low HbA1c, and a low hematocrit raises the erythrocyte sedimentation rate (ESR). Copper deficiency can cause anaemia together with low neutrophils.

Sources: [15] [16] [26]

References

  1. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: WHO; 2024. ISBN 978-92-4-008854-2. Table 2 (cutoffs, 5th percentile) and Table 5 (smoking adjustments). iris.who.int/server/api/core/bitstreams/f9f74397-1440-478d-a63c-26f29a01552f/content
  2. Corrons JLV, Casafont LB, Frasnedo EF. Concise review: how do red blood cells born, live, and die? Ann Hematol. 2021;100(10):2425-2433. PMID 34342697
  3. Mondal H, Zubair M. Hematocrit. In: StatPearls. StatPearls Publishing; 2024. PMID 31194416
  4. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-10. PMID 3838366
  5. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82(22):7580-4. PMID 3865178
  6. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol. 2009;46(4):387-93. PMID 19786207
  7. Gagliano-Jucá T, Pencina KM, Ganz T, et al. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018;315(6):E1185-E1193. PMID 30325657
  8. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID 29562364
  9. Jatenzo (testosterone undecanoate) capsules. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60
  10. Xyosted (testosterone enanthate) injection. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81
  11. Kyzatrex (testosterone undecanoate) capsules. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971
  12. Aveed (testosterone undecanoate) injection. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045
  13. Aguree S, Gernand AD. Plasma volume expansion across healthy pregnancy: a systematic review and meta-analysis of longitudinal studies. BMC Pregnancy Childbirth. 2019;19(1):508. PMID 31856759
  14. Smith JA. Exercise, training and red blood cell turnover. Sports Med. 1995;19(1):9-31. PMID 7740249
  15. Jandrić Balen M, Lukenda V, Jandrić I, et al. HbA1C - overall glycemia marker and hemolytic anemia indicator. Med Glas (Zenica). 2012;9(2):406-8. PMID 22926387
  16. Fabry TL. Mechanism of erythrocyte aggregation and sedimentation. Blood. 1987;70(5):1572-6. PMID 3663946
  17. Labcorp. Sample report, test 005009 (CBC With Differential/Platelet): reference intervals as printed for a 46-year-old woman (reported 09/15/2026) and a 15-year-old boy (reported 10/23/2024). files.labcorp.com/testmenu-d8/sample_reports/005009.pdf
  18. Labcorp. Sample report, test 005041 (Hemoglobin): reference interval as printed for a 26-year-old woman (2016). files.labcorp.com/testmenu-d8/sample_reports/005041.pdf
  19. Labcorp. Sample report, test 028142 (CBC, Platelet, No Differential): reference intervals as printed for a 60-year-old woman (reported 01/27/2020). files.labcorp.com/testmenu-d8/sample_reports/028142.pdf
  20. Quest Diagnostics. Test 510: Hemoglobin. Test directory: specimen, stability, methodology; reference range "See Laboratory Report". testdirectory.questdiagnostics.com/test/test-detail/510/hemoglobin?cc=PHP
  21. Alkhedaide AQ. Tobacco smoking causes secondary polycythemia and a mild leukocytosis among heavy smokers in Taif City in Saudi Arabia. Saudi J Biol Sci. 2020;27(1):407-411. PMID 31889864
  22. Epogen (epoetin alfa). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5
  23. Wang Q, Liu J, Hu S, et al. Establishment of reference intervals for complete blood count in healthy adults at different altitudes on the Western Sichuan Plateau. Front Med (Lausanne). 2025;12:1586778. PMID 40470042
  24. Leppänen EA, Gräsbeck R. Experimental basis of standardized specimen collection: effect of posture on blood picture. Eur J Haematol. 1988;40(3):222-6. PMID 3356238
  25. Mayer GA. Diurnal, postural and postprandial variations of hematocrit. Can Med Assoc J. 1965;93(19):1006-8. PMID 5319212
  26. Lazarchick J. Update on anemia and neutropenia in copper deficiency. Curr Opin Hematol. 2012;19(1):58-60. PMID 22080848
  27. Lippi G, Salvagno GL, Danese E, et al. Variation of red blood cell distribution width and mean platelet volume after moderate endurance exercise. Adv Hematol. 2014;2014:192173. PMID 25197280
  28. Fedele L, Bianchi S, Baglioni A, et al. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Biol. 1991;38(1):53-7. PMID 1899079
  29. Candiani GB, Vercellini P, Fedele L, et al. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand. 1990;69(5):413-5. PMID 2148663
  30. Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab. 2003;16(4):509-20. PMID 12793602
  31. Ylikorkala O, Tiitinen A, Hulkko S, et al. Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Hum Reprod. 1995;10(6):1470-4. PMID 7593517
  32. Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med. 2000;45(6):481-9. PMID 10900582
  33. Zhou YF, Yang DZ, Hu LN, et al. [Clinical trial on the effectiveness and safety of triptorelin in treatment of uterine leiomyoma]. Zhonghua Fu Chan Ke Za Zhi. 2005;40(7):460-3. PMID 16080872
  34. Chander S, Choo R, Danjoux C, et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys. 2005;62(3):719-24. PMID 15936551
  35. Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate. 1996;29(4):243-8. PMID 8876707
  36. Zoladex (goserelin implant). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
  37. Curtis KK, Adam TJ, Chen SC, et al. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male. 2008;11(4):157-61. PMID 18937151
  38. Lupron Depot (leuprolide acetate) 7.5 mg, 22.5 mg, 30 mg, 45 mg. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  39. Tye SC, de Vries ST, Mann JFE, et al. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Front Pharmacol. 2022;13:786767. PMID 35496307
  40. Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24(8):3495-505. PMID 27005463
  41. Smith JP, Bingaman SI, Mauger DT, et al. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials. 2010;2010(2):37-48. PMID 20890374
  42. Zucker I, Rainer Q, Pai RK, et al. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022;14(5):e25543. PMID 35800844
  43. Minder AE, Barman-Aksoezen J, Schmid M, et al. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. Ther Adv Rare Dis. 2021;2:26330040211065453. PMID 37181106
  44. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
  45. Yu EW, Kumbhani R, Siwila-Sackman E, et al. Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014;29(6):1380-6. PMID 24420643
  46. Vernekar SS, Goudar SS, Metgud M, et al. Effect of heat stable carbetocin vs oxytocin for preventing postpartum haemorrhage on post delivery hemoglobin-a randomized controlled trial. J Matern Fetal Neonatal Med. 2022;35(25):8744-8751. PMID 34763599
  47. Samimi M, Hosseiniara R, Akbari H, et al. Carbetocin versus oxytocin with or without tranexamic acid for preventing postpartum hemorrhage in cesarean delivery: a randomized controlled trial. BMC Pregnancy Childbirth. 2026;26(1):183. PMID 41593544
  48. Procrit (epoetin alfa). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c721ba4-ae19-417f-aae1-221ed1a0866a
  49. Retacrit (epoetin alfa-epbx). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374
  50. Lupron Depot 3.75 mg (leuprolide acetate). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c486b0-bd7b-4898-834d-8c656e5e73cb
  51. Ganirelix acetate injection. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e
  52. Refludan (lepirudin). FDA prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf
  53. Somatuline Depot (lanreotide). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d
  54. Trelstar (triptorelin pamoate). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  55. Signifor (pasireotide). FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
  56. Elura (capromorelin oral solution) for cats. FDA prescribing information. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4beb9c-f39b-4b23-9c35-f72a049a3250
  57. Wofford JA, Milliken MacKinnon A, Heinen E. Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial. J Feline Med Surg. 2025;27(11):1098612X251379924. PMID 41204815
  58. Chi Y, Peng Y, Zhang S, et al. A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides. Toxics. 2024;12(6). PMID 38922067
  59. Bessman JD, Gilmer PR, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol. 1983;80(3):322-6. PMID 6881096
  60. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20(3):222-30. PMID 23449069
  61. Coskun A, Braga F, Carobene A, et al. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters. Clin Chem Lab Med. 2019;58(1):25-32. PMID 31503541
  62. Buoro S, Carobene A, Seghezzi M, et al. Short- and medium-term biological variation estimates of red blood cell and reticulocyte parameters in healthy subjects. Clin Chem Lab Med. 2018;56(6):954-963. PMID 29303771
  63. LOINC 718-7: Hemoglobin [Mass/volume] in Blood. Regenstrief Institute. loinc.org/718-7

Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.